CD30, also known as TNFRSF8 (Tumor necrosis factor (TNF) receptor superfamily member 8), Ki-1 or D1S166E, is an approximately 64 kDa type I transmembrane glycoprotein consisting of 595 amino acids. This cell membrane protein is encoded by the chromosome of 1p36.22 and belongs to the tumor necrosis factor receptor (TNFR) superfamily. In malignant lymphoma, it is expressed on the Reed-Sternberg cells of classical Hodgkin's disease, anaplastic large cell lymphoma (ALCL), and so on. CD30 can interact with TRAF2 and TRAF5, mediating the signal transduction that evokes the activation of NF-kappa-B pathway. This receptor functions as a positive regulator of apoptosis, and also shows a limitation of the proliferative potential of autoreactive CD8 effector T cells and protects the body against autoimmunity. FcγRI, synonymously also referred to CD64, is a membrane spanning protein of 72 kDa and belongs to the immunoglobulin (Ig) supergene family. It has three extracellular Ig-like domains and is the only receptor that can efficiently bind monomeric IgG and aggregated IgG17. Hence, FcγRI is known to functions as a high-affinity Fcγ receptor where exists other two members FcγRII (CD32) and FcγRIII (CD16), but with low affinity. In humans, FcγRI is constitutively expressed on monocytes/macrophages, myeloid precursors, as well as follicular dendritic cells and its expression can also be induced on polymorphonuclear neutrophils via IFN-γ or G-CSF. Now, FcγRI is considered a great monocyte/macrophage-associated marker, normally used in flow cytometry (FCM) to identify leukemias with myelomonocytic differentiation.